Norway Chooses The Four-Type HPV Vaccine Gardasil(R) For The National Vaccination Programme

Cervical Cancer


The four-type (6,11,16,18) human papillomavirus (HPV) vaccine, Gardasil®, has been chosen by the Norwegian authorities for the national vaccination programme after the assessment of a variety of criteria, including efficacy in the prevention of cervical cancer, safety and evidence of long-lasting protection. All available data was considered, including new data presented during the 25th International Papillomavirus Conference (IPC) in May in Malmö, Sweden.

PG

Author: Leslie Carol Botha

Author, publisher, radio talk show host and internationally recognized expert on women's hormone cycles. Social/political activist on Gardasil the HPV vaccine for adolescent girls. Co-author of "Understanding Your Mood, Mind and Hormone Cycle." Honorary advisory board member for the Foundation for the Study of Cycles and member of the Society for Menstrual Cycle Research.